Herbal products represent an ever-increasing component of Western pharmacotherapy due in part to the perception that "natural" equates with safety. Current regulatory oversight of herbal products in many Western countries, including the United States, does not include evaluation of drug interaction liability prior to marketing. Consequently, systematic approaches for quantitative prediction of both the magnitude and likelihood of herb--drug interactions are nonexistent.

Drug interaction liability assessment of herbal products is more challenging than for conventional drugs because unlike most drug products, herbal products typically are mixtures of bioactive constituents that vary substantially between preparations.^[@bib1],[@bib2],[@bib3]^ Compounding this complexity is the often scant knowledge of specific causative constituents or systemic exposure of such constituents. Due to incomplete absorption and extensive presystemic clearance, herbal product constituents may reach sufficient concentrations in the intestine and liver to inhibit only first-pass extraction of sensitive substrates.^[@bib4]^ Consequently, traditional (static) prediction approaches frequently do not translate to the clinical setting for herb--drug interactions.

Recent drug--drug interaction guidelines suggest dynamic modeling and simulation approaches to predict complex interactions.^[@bib5],[@bib6]^ Extension of this approach to herb--drug interactions is a logical step to facilitate prospective evaluation of these interactions. As with drug--drug interactions,^[@bib7],[@bib8]^ physiologically based pharmacokinetic (PBPK) modeling may be used to improve *in vitro* to *in vivo* extrapolation of herb--drug interactions. Well-characterized herbal products are needed to develop a quantitative framework.

Milk thistle preparations are top-ten selling herbal products in the United States.^[@bib9]^ The crude extract, silymarin, contains at least seven flavonolignans and one flavonoid.^[@bib10]^ The semipurified extract, silibinin, contains roughly a 1:1 mixture of the flavonolignans silybin A and silybin B and represents an exemplar herbal product for initial model development. First, silybin A and silybin B have been purified in quantities sufficient to recover requisite *in vitro* parameters.^[@bib11],[@bib12]^ Second, *in vitro* studies have demonstrated both reversible and mechanism-based inhibition of the key drug metabolizing enzymes CYP2C9^[@bib13],[@bib14],[@bib15]^ and CYP3A4.^[@bib13],[@bib14],[@bib16]^ Third, *in vitro* to *in vivo* extrapolation has been inconsistent.^[@bib17],[@bib18],[@bib19]^ Based on these observations, the objective of this work was to advance the mechanistic understanding of this herb--drug interaction using PBPK modeling and simulation with warfarin and midazolam as probe substrates. The models were evaluated through a proof-of-concept clinical study in healthy volunteers. Results could help develop guidelines for prospective evaluation of herb--drug interaction liability.

Results
=======

Modeling and simulation
-----------------------

*PBPK model generation and initial evaluation.* Simulated probe substrate concentrations closely approximated previously published concentration--time profiles for both warfarin^[@bib20]^ and midazolam^[@bib21]^ under baseline conditions (data not shown). Model-predicted primary endpoints (area under the curve (AUC) and *C*~max~ for (*S*)-warfarin and midazolam) were within the prespecified criterion (30%) for acceptable model performance (**[Table 1](#tbl1){ref-type="table"}**).

*Prediction of silibinin--drug interaction magnitude.* Simulations of a previously reported milk thistle-midazolam interaction, assuming reversible CYP3A inhibition solely due to silybin A and silybin B, demonstrated negligible changes in the midazolam concentration--time profile (**[Figure 1](#fig1){ref-type="fig"}**). The milk thistle product tested, silymarin, contained 100 mg of silybin A and 180 mg of silybin B and was administered daily for 14 days.^[@bib18]^ Simulations assuming mechanism-based CYP3A inhibition predicted a 30% and 60% increase in midazolam *C*~max~ and AUC, respectively; increases of 6% and 3% in midazolam *C*~max~ and AUC, respectively, were reported^[@bib18]^ (**[Figure 1](#fig1){ref-type="fig"}**).

Simulations of the silibinin--warfarin interaction with a higher dose of silibinin (1,650 mg/day, or 720 mg silybin A plus 930 mg silybin B/day; see below), assuming reversible CYP2C9 inhibition only, predicted negligible changes (\<5%) in all pharmacokinetic outcomes (**[Figure 2a](#fig2){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**). Simulations of the high-dose silibinin--midazolam interaction assuming reversible CYP3A inhibition predicted no change in midazolam *t*~1/2~ and ≤5% increase in both *C*~max~ and AUC (**[Figure 2b](#fig2){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**). Simulations assuming mechanism-based CYP3A inhibition predicted a 2-, 5-, and 1.5-fold increase in *C*~max~, AUC, and *t*~1/2~, respectively (**[Table 2](#tbl2){ref-type="table"}**).

Proof-of-concept clinical evaluation
------------------------------------

*Silibinin content in test product.* A single lot (\#304090) of Siliphos capsules, labeled to contain 60 mg silibinin, was selected. The capsules were overfilled consistently, containing 69.1 ± 4.28 mg silibinin represented as 30.3 ± 1.88 mg silybin A and 38.9 ± 2.39 mg silybin B. The capsules also contained minor amounts of the regioisomers isosilybin A (1.55 ± 0.09 mg) and isosilybin B (0.94 ± 0.06 mg).

*Study subjects.* All enrolled subjects completed the study (**Supplementary Table S2**). The study drugs and silibinin generally were well tolerated. One subject experienced mild gastrointestinal upset following the first dose of silibinin. The effect was deemed likely to be drug related by the study physician but was transient and did not limit the subject\'s continued participation. During Clinical and Translational Research Center (CTRC) visits, four subjects (two in both phases) reported mild headaches attributed to caffeine withdrawal. No international normalized ratio elevations from baseline were observed following warfarin administration.

*CYP2C9 genotyping.* All enrolled subjects consented to genotyping. Ten subjects were homozygous for the reference *CYP2C9\*1* allele. Two subjects carried one copy of the reference allele and either the *CYP2C9\*2* or *CYP2C9\*3* allele.

*Effects of high-dose silibinin on warfarin and midazolam pharmacokinetics.* The effects of high-dose silibinin (1,650 mg/day) were compared to baseline oral pharmacokinetics of warfarin and midazolam. Due to the reported mechanism-based inhibition of CYP3A *in vitro*,^[@bib14],[@bib16]^ silibinin was administered three times daily for 6 days prior to administration of the probe substrates. Silibinin constituents were not expected to accumulate during the administration period due to short reported half-lives (\<4 hours).^[@bib22]^ One subject demonstrated poor goodness-of-fit statistics for the *t*~1/2~ of both warfarin enantiomers in both phases (*R*^2^ \< 0.85). Accordingly, data from this subject were excluded from analysis of AUC~0--48~ and *t*~1/2~.

Warfarin enantiomers were absorbed rapidly during both study phases, with median *t*~max~ occurring at 1.25 and 1.5 hours for (*R*)- and (*S*)-warfarin, respectively (**[Figure 2a](#fig2){ref-type="fig"}**). Coadministration with silibinin did not alter median (*S*)-warfarin *t*~max~ but delayed median (*R*)-warfarin *t*~max~ by 15 minutes. Relative to control (baseline), silibinin decreased (*R*)-warfarin geometric mean *C*~max~ by 17% (**[Figure 3a](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**) and AUC~0--48~ by 15% (**[Figure 3b](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**). Silibinin decreased geometric mean (*S*)-warfarin *C*~max~ by 2% (**[Figure 3c](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**). Geometric mean AUC~0--48~ of (*S*)-warfarin increased by 13% (**[Figure 3d](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**), with three subjects lying outside the predefined no effect range (0.75--1.33). The 90% confidence intervals for the (*S*)-warfarin primary endpoints (*C*~max~ and AUC) lay within the predefined no effect range (**[Table 2](#tbl2){ref-type="table"}**).

The rapid absorption of midazolam was unaltered by coadministration with silibinin, with median *t*~max~ occurring at 0.5 hours (**[Figure 2b](#fig2){ref-type="fig"}**). Relative to control, silibinin increased midazolam geometric mean *C*~max~ by 20% (**[Figure 3e](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**) and AUC~0--inf~ by 9% (**[Figure 3f](#fig3){ref-type="fig"}**; **[Table 2](#tbl2){ref-type="table"}**). Except for one subject (2.3-fold increase), treatment/control ratios of AUC~0--inf~ lay within the predefined no effect range (**[Figure 3f](#fig3){ref-type="fig"}**). The 90% confidence interval for midazolam treatment/control ratio of *C*~max~ extended above, whereas that of AUC~0--inf~ lay within, the predefined no effect range (**[Table 2](#tbl2){ref-type="table"}**).

The sampling strategy was not optimized for recovery of silybin A and silybin B pharmacokinetic outcomes; as such, these outcomes were interpreted for qualitative rather than quantitative purposes. The median *t*~max~ of silybin A and silybin B following the initial administration of silibinin (3 and 3.5 hours, respectively) nearly coincided with the second administration of silibinin (**[Figure 2c](#fig2){ref-type="fig"}**). Geometric mean *C*~max~ for silybin A was more than double that for silybin B (**[Table 2](#tbl2){ref-type="table"}**). Geometric mean *t*~1/2~ of both silybin A and silybin B was \~5 hours (**[Table 2](#tbl2){ref-type="table"}**).

DISCUSSION
==========

Although herbal product usage continues to increase, current regulatory guidelines in several Western countries do not request premarket evaluation of herb--drug interaction liability. Investigations into such liabilities are fraught with inconsistent results due to the lack of a standard system for evaluation, high compositional variation between herbal products, and uncertainty about causative constituents. Unlike conventional drug products, the relative composition of herbal products may vary substantially depending on weather conditions, product collection and storage methods, and processing procedures.^[@bib4]^ Accurate predictions of herb--drug interaction liability require not only identification and quantification of causative constituents, but also measures of exposure in organs with metabolic capability. Silibinin was selected as an exemplar herbal product due to a well-characterized composition, availability of inhibitory kinetic parameters from individual constituents, and disparate impact of milk thistle products on victim drug pharmacokinetics in previous clinical studies.^[@bib17],[@bib18],[@bib19]^ A PBPK modeling and simulation approach was used to address the challenges inherent to investigation of herb--drug interaction liability.

Warfarin is a widely used oral anticoagulant with a narrow therapeutic window. Warfarin is associated with a notoriously complicated pharmacotherapy due in part to myriad drugs and herbal products that alter the metabolism or anticoagulant activity of warfarin. As the clearance of the more pharmacologically active (*S*)-enantiomer is mediated primarily by CYP2C9, inhibition of this enzyme can lead to increased risk of bleeding. Silymarin was shown previously to increase systemic exposure to the CYP2C9/3A substrate losartan,^[@bib19]^ prompting evaluation of the interaction potential between milk thistle and warfarin. Of the milk thistle constituents whose CYP2C9 interaction liability has been evaluated *in vitro*, silybin A and silybin B were the most potent.^[@bib15]^ These observations led to the selection of silibinin, which consists primarily of these two constituents, for clinical evaluation.

Relative to control, silibinin unexpectedly decreased both the geometric mean *C*~max~ and AUC~0--last~ of (*R*)-warfarin. Clinical manifestation of the previously reported CYP1A2 induction by a milk thistle extract^[@bib23]^ is consistent with this decrease in exposure. In contrast to the doubling of losartan exposure following administration of silymarin, high-dose silibinin did not increase geometric mean (*S*)-warfarin exposure to a clinically relevant extent. However, increases above 33% were observed in three subjects, indicating that the CYP2C9 interaction potential of silibinin cannot be disregarded completely. Consistent with the expected decrease in (*S*)-warfarin clearance, the subject carrying the reduced function *CYP2C9\*3* allele demonstrated prolonged warfarin exposure, which was not captured in the 48-hour sampling window. As such, the AUC and *t*~1/2~ for this subject were excluded from analysis.

Modeling and simulation of the silibinin--warfarin interaction demonstrated that the rapid clearance of the silibinin constituents precluded marked inhibition of warfarin clearance. Sensitivity analysis of this interaction potential demonstrated that 10-fold increases in silybin A or silybin B inhibition potency (reversible *K*~i~) would lead to roughly 15% increases in (*S*)-warfarin AUC (**Supplementary Figure S1**). Extensive intestinal and hepatic conjugation of silybin A and silybin B followed by rapid elimination likely would limit the interaction potential to first-pass clearance of sensitive substrates. Warfarin is not sensitive to first-pass elimination and is cleared only upon subsequent passages through the liver, at which time any reversible inhibition of CYP2C9 by silybin A and silybin B would be abated. In contrast, losartan has a low bioavailability (33%) that is attributed, in part, to first-pass elimination.^[@bib24]^ This observation, coupled with the differences in study population and herbal product tested, could explain the difference between the reported interaction with losartan^[@bib19]^ and the lack of interaction with warfarin in the present study. Collectively, these observations suggest examination of other CYP2C9 substrates sensitive to first-pass elimination, such as fluvastatin, to understand fully the milk thistle-CYP2C9 interaction potential.

Midazolam is a gold standard CYP3A probe substrate metabolized extensively by intestinal and hepatic enzymes. Inhibition of CYP3A at either site can increase systemic exposure to midazolam; inhibition of hepatic CYP3A also can increase *t*~1/2~. Milk thistle constituents, including silybin A and silybin B, have been shown to be reversible and mechanism-based inhibitors of CYP3A activity in both human liver microsomes and expressed enzyme systems.^[@bib13],[@bib14],[@bib16]^ Previous clinical interaction studies with midazolam^[@bib17],[@bib18]^ have demonstrated limited interaction liability with the milk thistle product silymarin, albeit the doses administered were not sufficient to determine the difference between reversible and mechanism-based inhibition of CYP3A (**[Figure 1](#fig1){ref-type="fig"}**). The "supratherapeutic" silibinin dose in the current study was selected to provide a large range between the predicted interaction based on reversible and mechanism-based inhibition of CYP3A and to maximize the ability to observe a clinical interaction. The lack of an interaction observed in all but one subject indicated that the CYP3A interaction liability for silibinin is low and is more consistent with reversible than mechanism-based inhibition (assuming inhibition indeed occurred). The current work represents another example of a potential mechanism-based inhibitor identified *in vitro*^[@bib16]^ that does not manifest clinically.

Modeling and simulation of the silibinin--midazolam interaction indicated that the low interaction potential is due, in part, to the lower inhibition potency of the silibinin constituents toward CYP3A compared to CYP2C9 (**[Table 3](#tbl3){ref-type="table"}**). Ten-fold increases in inhibition potency of silybin A and silybin B toward CYP3A activity increased midazolam exposure by roughly 25% (**Supplementary Figure S1** and **Supplementary Materials and Methods**). These observations indicated that at the predicted exposures, the constituents would need to be 10-fold more potent to demonstrate any clinically relevant interaction with CYP3A. The large predicted increase in midazolam exposure incorporating mechanism-based inhibition further supported the hypothesis that products with limited systemic exposure (first posited with fruit juices)^[@bib25]^ need to be mechanism-based inhibitors of CYP enzymes to perpetrate clinically relevant interactions.

One limitation to the current work is that silybin A and silybin B clearance parameters were recovered by fitting the model to data obtained from hepatitis C patients administered a product (silymarin) that contained additional constituents not present in silibinin.^[@bib26]^ *In vitro* determination of silibinin clearance parameters would provide a true bottom-up modeling approach and reduce complexities inherent to pharmacokinetic data from patients with hepatic disease. Alternatively, disease-related parameters could be used to develop a hepatitis C virtual population before fitting the PBPK model with the observed pharmacokinetic data, facilitating recovery of disease-independent silibinin clearance parameters.^[@bib27],[@bib28],[@bib29]^

In summary, prospective evaluation of herb--drug interactions, consistent with that for drug--drug interactions, largely has been ignored due to substantial compositional variability inherent to herbal products, multiple inhibitory constituents, varying inhibition mechanisms, and relative lack of regulatory oversight. The PBPK interaction model developed in the current work incorporated *in vitro* inhibition kinetic parameters and systemic exposure estimates of individual constituents for the exemplar herbal product, silibinin. Simulations of the silibinin--warfarin and silibinin--midazolam interactions accurately predicted minimal clinical interaction liability. This work demonstrated the utility and predictive power of PBPK modeling and simulation, which could be extended to investigate scenarios (e.g., wide dosing ranges, tissue exposure assessment, and herbal product composition variation) and patient populations (e.g., pediatric, geriatric, and pregnant women) not amenable to clinical investigation. Refinement of the PBPK model by recovering disease-independent silibinin clearance parameters and incorporating alternate victim drugs, including losartan, will enhance confidence in model predictions and generalizability. This framework represents an initial step to establishing a systematic approach that can be applied to other combinations of herbal products and conventional drugs under various clinical scenarios to identify potential clinically significant herb--drug interactions, predict the extent of those interactions, and ultimately help guide pharmacotherapeutic decisions.

METHODS
=======

*PBPK model development.* The base model structure was adapted from the literature^[@bib30]^ (**[Figure 4](#fig4){ref-type="fig"}**), incorporating physiologic parameters obtained from the International Commission on Radiological Protection.^[@bib31]^ Warfarin partition coefficients (*K*~p~s)^[@bib32]^ and binding parameters^[@bib33]^ were obtained from the literature (**[Table 3](#tbl3){ref-type="table"}**); absorption rate constants (*k*~a~*s*) and clearance parameters were obtained by fitting the PBPK model to previously reported plasma concentration--time profiles.^[@bib20]^ The reversible inhibition constant (*K*~i~) of (*R*)-warfarin toward CYP2C9 activity was obtained from the literature.^[@bib34]^ Midazolam *K*~p~*s* and *k*~a~ were obtained from the literature^[@bib30],[@bib35]^; intestinal and hepatic clearance parameters were extrapolated from *in vitro* data^[@bib16]^ as described^[@bib36],[@bib37]^ (**[Table 3](#tbl3){ref-type="table"}**). Silybin A and silybin B *K*~p~*s* were predicted from physicochemical properties^[@bib38]^ using GastroPlus (version 8.0; Simulations Plus, Lancaster, CA). Silibinin binding parameters were obtained from the literature^[@bib39]^; clearance parameters were generated by fitting the PBPK model to plasma concentration--time data from hepatitis C patients receiving silymarin^[@bib26]^ (**[Table 3](#tbl3){ref-type="table"}**). Silybin A and silybin B mechanism-based (*K*~I~, *k*~inact~) and reversible inhibition kinetic parameters were obtained from the literature.^[@bib15],[@bib16]^ Mechanism-based inhibition of CYP2C9 was not considered based on a previous publication showing no IC~50~ shift using (*S*)-warfarin as the probe substrate.^[@bib15]^

*PBPK interaction model simulations.* PBPK models were developed for midazolam, (*R*)-warfarin, (*S*)-warfarin, silybin A, and silybin B using Berkeley Madonna (version 8.3; University of California at Berkeley, Berkeley, CA) with code compiled in MEGen^[@bib40]^ (version 0.5; UK Health & Safety Laboratory, Buxton, UK) (**Supplementary Materials and Methods**). The PBPK model for perpetrator (silybin A and silybin B) and victim (warfarin or midazolam) compounds were linked through the reversible or mechanism-based inhibition of victim probe substrate. Initial simulations used doses of probe substrates and milk thistle products reported in previous studies. Simulations were considered accurate if the predicted primary pharmacokinetic outcomes (AUC and *C*~max~ for (*S*)-warfarin and midazolam) were within 30% of observed outcomes. Following initial model evaluation, simulations were conducted with a higher dose of silibinin (1,650 mg/day) to determine whether a clinically important interaction is possible. Pharmacokinetic outcomes from the simulated profiles were recovered via noncompartmental analysis using Phoenix WinNonlin (version 6.3; Pharsight, Cary, NC).

*Analysis of silibinin product.* Siliphos capsules (*n* = 28) (Thorne Research, Dover, ID) were analyzed using a modification of previously described methods^[@bib41],[@bib42]^ to ensure purity and content. Briefly, the contents of each capsule were weighed and extracted twice with 2 ml acetone. The extract was vortex mixed and centrifuged (13,000*g* for 2 minutes); the supernatant was transferred to a clean vial. Milk thistle constituents were quantified using an Acquity UPLC system with an HSS-T3 1.8 µm (2.1 × 100 mm) Acquity column and Empower 3 software (Waters, Milford, MA). Standards and Siliphos capsule extracts were analyzed using a gradient from 30:70 to 55:45 methanol:water (0.1% formic acid) over 5.0 minutes at a flow rate of 0.6 ml/minute at 50 °C; peaks were detected at 288 nm.

*Proof-of-concept clinical study.* Healthy volunteers (six men and six nonpregnant women) were enrolled in an open-label, fixed sequence crossover study conducted at the UNC CTRC. The study protocol was approved by the UNC Office of Human Research Ethics Biomedical Institutional Review Board and the CTRC Advisory Committee. Eligibility to participate was based on screening evaluation and inclusion/exclusion criteria (**Supplementary Table S1**). Written informed consent was obtained from each subject prior to enrollment.

The first (control) phase consisted of administration of 10 mg warfarin (Coumadin; Bristol Meyers Squibb, Princeton, NJ), 10 mg vitamin K (Mephyton; Aton Pharma, Lawrenceville, NJ), and 5 mg midazolam syrup (Ranbaxy; Jacksonville, FL). A negative pregnancy result was required before drug administration to women of childbearing potential. Vital signs (blood pressure, temperature, respiratory rate, pulse, and oxygen saturation) were obtained at baseline and every 15 minutes for the first 2 hours. All subjects underwent an international normalized ratio with prothrombin time. Blood (7 ml) was collected through an intravenous line before and from 0.25--12 hours following drug administration. Subjects continued to fast until after the 4-hour blood collection, when meals and snacks, devoid of fruit juices and caffeinated beverages, were provided. Subjects returned to the CTRC 24 and 48 hours post-drug administration for blood collection. Optimal study design simulations^[@bib43]^ of previously reported clinical data^[@bib20]^ demonstrated that a 0--48-hour collection was an accurate surrogate of total systemic exposure (AUC~0--inf~) for warfarin. Plasma was collected and stored at −80 °C pending analysis by high-performance liquid chromatography tandem mass spectrometry (HPLC/MS-MS).

Following at least a 14-day washout, subjects received 480 mg silibinin (based on labeled content) to self-administer three times daily for 7 days. Each subject received his/her silibinin in a blister pack and was asked to complete a pill diary documenting the time of administration. Subjects were contacted at least twice during the week of silibinin self-administration to monitor compliance and adverse events, which were graded using a validated Adverse Events Scale. Subjects returned to the CTRC on day 7 for concomitant administration of silibinin, warfarin, vitamin K, and midazolam. Plasma was collected and stored as described for the first phase.

*Analysis of plasma for warfarin enantiomers, midazolam, silybin A, and silybin B.* Concentrations of all analytes were quantified using a Sciex (Framingham, MA) API4000 Qtrap HPLC-MS/MS triple quadrupole mass spectrometer fitted with a Turbo ionspray interface operated in the positive ion mode. Plasma was treated with acetonitrile (6 volumes) containing the internal standard, warfarin-d~5~ (Toronto Research Chemicals; Toronto, Canada) or 1′-hydroxymidazolam-d~4~ (Cerilliant, Round Rock, TX), and centrifuged (3,000*g*). The supernatant was injected into the HPLC-MS/MS system. Warfarin enantiomers were separated on a Supelco Astec Chirobiotic V 15 cm × 2.1 mm 5 micron chiral column (Sigma Aldrich; St Louis, MO) and eluted with an isocratic mixture consisting of 75% 5 mmol/l ammonium acetate containing 0.01% (v/v) formic acid and 25% acetonitrile (flow rate, 0.4 ml/minute). Midazolam was eluted with a binary gradient mixture consisting of 10 mmol/l ammonium formate containing 1% (v/v) isopropyl alcohol and 0.1% (v/v) formic acid and methanol on a Varian Polaris C18-A 20 cm × 2.0 mm 5 micron column (Agilent, Santa Clara, CA) (flow rate, 0.65 ml/minute). Silybin A and silybin B were eluted with an isocratic mixture consisting of 44% water, 56% methanol, and 0.1% (v/v) formic acid on an Agilent Zorbax XDB C18 15 cm × 3.0 mm 3.5 micron column (Agilent) (flow rate, 0.7 ml/minute). Analyte concentrations were determined by interpolation from a linear standard curve with an assay dynamic range of 0.5--10,000 nmol/l (warfarin enantiomers) or 0.5--5,000 nmol/l (midazolam, silybin A, silybin B). Analytical methods were validated according to US Food and Drug Administration guidelines.^[@bib44]^ Inter- and intraday variability for all analytes was less than 10%.

*Pharmacokinetic analysis.* Pharmacokinetic outcomes were recovered by noncompartmental analysis using Phoenix WinNonlin. Concentrations below the limit of quantification were excluded. The terminal elimination rate constant (λ~z~) was estimated by linear regression of the terminal portion of the log-transformed concentration--time profile using at least three data points. The terminal half-life (*t*~1/2~) was calculated as ln2/λ~z~. The maximum observed concentration (*C*~max~), time to reach *C*~max~ (*t*~max~), and last measured concentration (*C*~last~) were obtained directly from the concentration--time profile. AUC from time zero to *C*~last~ (AUC~0--last~) was determined using the trapezoidal method with linear up/log down interpolation. The AUC from time zero to infinity (AUC~0--inf~) was calculated as the sum of AUC~0--last~ and the ratio of *C*~last~ to λ~z~.

*Genotyping for common CYP2C9 variants.* *CYP2C9\*2* and *\*3* polymorphisms were determined using a previously published polymerase chain reaction restriction fragment length polymorphism assay.^[@bib45]^

*Statistical analysis.* All statistical analyses were conducted using SAS (version 9.2; SAS Institute, Cary, NC). The sample size for the proof-of-concept study (*n* = 12 evaluable subjects) was calculated based on 80% power to detect a 25% change in the primary endpoints with a type I error of 0.05; the primary endpoints were the treatment/control ratios of log-transformed AUC~0--48~ ((*S*)-warfarin) or AUC~0--inf~ (midazolam) and *C*~max~ ((*S*)-warfarin and midazolam), and the predefined no effect range was 0.75--1.33.^[@bib5],[@bib6]^ Intraindividual variability in midazolam and warfarin AUC and *C*~max~ were assumed to be \~20%.^[@bib46],[@bib47],[@bib48]^ Secondary outcomes, *t*~1/2~ and *t*~max~, were evaluated using a paired two-tailed Student\'s *t*-test on log-transformed data or Wilcoxon signed-rank test as appropriate, with 90% confidence intervals and ranges reported for *t*~1/2~ and *t*~max~, respectively. A *P* value \<0.05 was considered statistically significant.
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![Mean concentration--time profile (0--6 hours) of midazolam in 19 healthy volunteers following an 8 mg oral midazolam dose given alone (open symbols) or following a 14-day treatment with milk thistle product (solid symbols).^[@bib18]^ Lines denote physiologically based pharmacokinetic model simulations of the midazolam concentration--time profile when given alone (black) or with milk thistle (green). The dotted green line denotes incorporation of reversible inhibition of CYP3A, whereas the dashed green line denotes incorporation of mechanism-based inhibition of CYP3A. Symbols and error bars denote observed means and SDs, respectively, and were obtained from ref. [@bib18].](psp201369f1){#fig1}

![Geometric mean concentration--time profile of (**a**) warfarin, (**b**) midazolam, and (**c**) silibinin in 12 healthy volunteers following a 10 mg oral dose of warfarin or 5 mg oral dose of midazolam given alone (open symbols) or following a 7-day treatment with silibinin (solid symbols). Lines in **a** and **b** denote physiologically based pharmacokinetic (PBPK) model simulations of the concentration--time profiles when the probe substrates were given alone (black) or with silibinin (green). Blue and orange lines in **c** denote PBPK model simulations of the concentration--time profiles of silybin A and silybin B, respectively. Symbols and error bars denote observed geometric means and upper limits of the 90% confidence interval, respectively.](psp201369f2){#fig2}

![Effects of silibinin (1,650 mg/day for 7 days) on (**a**,**c**,**e**) *C*~max~ and (**b**,**d**,**f**) AUC of (**a**,**b**) (*R*)-warfarin, (**c**,**d**) (*S*)-warfarin, and (**e**,**f**) midazolam in 12 healthy volunteers following oral administration of warfarin (10 mg) and midazolam (5 mg). Open symbols connected by solid lines denote individual values. Solid symbols connected by dashed lines denote geometric means.](psp201369f3){#fig3}

![Base physiologically based pharmacokinetic model structure. Model structure was modified from the literature.^[@bib30]^ Organ weights and blood flows were obtained from the International Commission on Radiological Protection.^[@bib31]^ Following oral administration, drug transfer from dosing compartment to intestine is driven by the oral absorption rate constant (*k*~a~). Drug clearance (Cl) is mediated by metabolic processes in the intestine and liver. The pancreas and spleen were combined into a hybrid "organ" designated as PSP.](psp201369f4){#fig4}

###### Comparison of previously published and model-predicted pharmacokinetic outcomes
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###### Comparison of proof-of-concept clinical study outcomes to physiologically based pharmacokinetic model predictions
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###### Physiologically based pharmacokinetic model input parameters
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